West Virginia House Bill HB2912

West Virginia 2025 Regular Session

• Introduced: 2/24/25
• Refer: 2/24/25

Caption

To provide for the coordination of programs to prevent and treat obesity

Summary

HB2912 would require accident and sickness insurance coverage in West Virginia for GLP-1 class medications when prescribed by a licensed provider and supported by a valid prescription. GLP-1 drugs are commonly used to treat diabetes and, increasingly, obesity and related metabolic conditions. The bill adds a new section to Chapter 33, Article 15 of the West Virginia Code to create this coverage mandate. In practical terms, the measure would shift state insurance law by directing health insurers subject to Article 15 to cover this medication class, rather than leaving coverage decisions entirely to plan design or medical necessity policies. The bill’s caption and context indicate a broader policy goal of coordinating programs to prevent and treat obesity, suggesting the coverage mandate is intended to improve access to obesity treatment as well as other GLP-1 uses.

Impact

The bill would amend West Virginia insurance law by adding §33-15-24 and requiring coverage of GLP-1 class medications for insured individuals with a valid prescription. This would affect accident and sickness insurance policies regulated under Article 15, likely including commercial health plans subject to state coverage mandates. The practical effect would be to expand insurer obligations and potentially increase utilization and premium costs, while improving access for patients using GLP-1 medications for diabetes, obesity, or related conditions.

Sentiment

Based on the limited available context, the bill appears to be presented in a supportive, policy-driven manner focused on obesity prevention and treatment. There are no recorded committee transcripts or votes in the provided materials, so there is no direct evidence of opposition or amendment debate. The overall framing suggests a health-access and treatment-expansion approach rather than a controversial procedural measure.

Contention

The main likely point of contention is the insurance coverage mandate itself: insurers and cost-conscious lawmakers may object to requiring coverage for GLP-1 medications because of their high price and potential impact on premiums, while supporters would emphasize medical necessity and access for patients with obesity, diabetes, or other qualifying conditions. Another possible issue is the breadth of the mandate, since the bill covers the GLP-1 class generally and does not specify clinical criteria beyond a valid prescription, which could raise questions about utilization management and scope of coverage.